Novo Nordisk Launches Oral Wegovy Pill in US Amid Competitive Market
Novo Nordisk has introduced its oral Wegovy pill in the United States, offering a needle-free alternative to injectable weight-loss treatments. Priced between $149 and $299 per month, the pill aims to capture cash-paying consumers in a competitive market dominated by Eli Lilly's Zepbound.
Insights:
Novo Nordisk A/S has launched its once-daily oral Wegovy pill in the United States on January 6, 2025, following the U.S. Food and Drug Administration's approval in December 2024. This strategic move aims to provide a needle-free alternative to injectable weight-loss treatments, addressing the company's profit warnings and declining share prices in 2025. The pill, priced between $149 and $299 per month depending on dosage, targets cash-paying consumers who lack insurance coverage.
